Recorlev

Active Ingredient(s): Levoketoconazole
FDA Approved: * December 30, 2021
Pharm Company: * STRONGBRIDGE DUBLIN LTD

Levoketoconazole, sold under the brand name Recorlev, is a steroidogenesis inhibitor that used for the treatment of Cushing's syndrome.[2][3][4][5] Levoketoconazole was approved for medical use in the United States in December 2021.[6][7] Levoketoconazole is the levorotatory or (2S,4R) enantiomer of ketoconazole,[3][4][5] and it is an inhibitor of the... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.